These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 30991446)
1. Incorporating Weight Loss Medications Into Hepatology Practice for Nonalcoholic Steatohepatitis. Do A; Kuszewski EJ; Langberg KA; Mehal WZ Hepatology; 2019 Oct; 70(4):1443-1456. PubMed ID: 30991446 [TBL] [Abstract][Full Text] [Related]
2. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Vilar-Gomez E; Martinez-Perez Y; Calzadilla-Bertot L; Torres-Gonzalez A; Gra-Oramas B; Gonzalez-Fabian L; Friedman SL; Diago M; Romero-Gomez M Gastroenterology; 2015 Aug; 149(2):367-78.e5; quiz e14-5. PubMed ID: 25865049 [TBL] [Abstract][Full Text] [Related]
3. Nonalcoholic steatohepatitis diagnosis and treatment from the perspective of patients and primary care physicians: a cross-sectional survey. Nadolsky K; Cryer DR; Articolo A; Fisher T; Schneider J; Rinella M Ann Med; 2023 Dec; 55(1):2211349. PubMed ID: 37171239 [TBL] [Abstract][Full Text] [Related]
5. Nonalcoholic steatohepatitis medical patient journey from the perspective of hepatologists, gastroenterologists and patients: a cross-sectional survey. Rinella M; Cryer DR; Articolo A; Fisher T; Schneider J; Nadolsky K BMC Gastroenterol; 2022 Jul; 22(1):335. PubMed ID: 35811319 [TBL] [Abstract][Full Text] [Related]
6. [Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management]. Kim SK; Kim KI; Kim SR Yakugaku Zasshi; 2019; 139(9):1147-1153. PubMed ID: 31474630 [TBL] [Abstract][Full Text] [Related]
7. Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study. Barritt AS; Gitlin N; Klein S; Lok AS; Loomba R; Malahias L; Powell M; Vos MB; Weiss LM; Cusi K; Neuschwander-Tetri BA; Sanyal A Contemp Clin Trials; 2017 Oct; 61():33-38. PubMed ID: 28735109 [TBL] [Abstract][Full Text] [Related]
8. What Does the Future Hold for Patients With Nonalcoholic Steatohepatitis: Diagnostic Strategies and Treatment Options in 2021 and Beyond? Alkhouri N; Tincopa M; Loomba R; Harrison SA Hepatol Commun; 2021 Nov; 5(11):1810-1823. PubMed ID: 34499435 [TBL] [Abstract][Full Text] [Related]
9. Nonalcoholic Fatty Liver Disease and Fibrosis in Youth Taking Psychotropic Medications: Literature Review, Case Reports, and Management. Gracious BL; Bhatt R; Potter C J Child Adolesc Psychopharmacol; 2015 Oct; 25(8):602-10. PubMed ID: 26447642 [TBL] [Abstract][Full Text] [Related]
10. Approach to the Patient With Nonalcoholic Fatty Liver Disease. Belfort-DeAguiar R; Lomonaco R; Cusi K J Clin Endocrinol Metab; 2023 Jan; 108(2):483-495. PubMed ID: 36305273 [TBL] [Abstract][Full Text] [Related]
11. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. Tokushige K; Ikejima K; Ono M; Eguchi Y; Kamada Y; Itoh Y; Akuta N; Yoneda M; Iwasa M; Yoneda M; Otsuka M; Tamaki N; Kogiso T; Miwa H; Chayama K; Enomoto N; Shimosegawa T; Takehara T; Koike K J Gastroenterol; 2021 Nov; 56(11):951-963. PubMed ID: 34533632 [TBL] [Abstract][Full Text] [Related]